April 09, 2024
Alkermes Announces Positive Topline Results From Phase 1b Study of ALKS 2680 Demonstrating Improved Wakefulness in Patients With Narcolepsy Type 2 a...
April 08, 2024
Alkermes Presents Analyses From Long-Term Safety Study of LYBALVI® (olanzapine and samidorphan) at 2024 Congress of the Schizophrenia International ...
March 07, 2024
Alkermes Announces Appointment of Nancy S. Lurker to Board of Directors
More than 200 Alkermes employees recently took time out of their normal work day to contribute their time and talents to a variety of local Massachusetts nonprofit organizations as part of our fifteenth Alkermes in Action employee volunteer day.
In celebration of International Women's Day, three senior female leaders at Alkermes reflected on their career journeys and their efforts to inspire inclusion.
Alkermes employees work with urgency -- in the laboratory, in the clinic and in the community -- seeking to make a meaningful difference for people living with complex and difficult-to-treat diseases. For many of our employees, this work is part of their personal mission to help patients, families and communities.
Neuroscience
Olanzapine and samidorphan - Schizophrenia or Bipolar I Disorder (pediatric)
ALKS 2680 - Narcolepsy
Orexin Agonists - Non-Orphan Indications